Information Provided By: 
Fly News Breaks for October 18, 2018
IMMU
Oct 18, 2018 | 16:07 EDT
Piper Jaffray analyst Joseph Catanzaro started Immunomedics with an Overweight rating and $33 price target, stating that he believes its Phase 2 data in triple negative breast cancer "fully support" an accelerated U.S. approval. He could see robust adoption in this setting leading to U.S. sales over $1B by 2028, Catanzaro tells investors. Sacituzumab has reported "impressive" data in both urothelial bladder cancer and ER+/HER2- breast cancer, which could also be "blockbuster opportunities," the analyst added.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
